NYMC Faculty Publications
The Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Postangioplasty Restenosis
Author Type(s)
Faculty
DOI
10.1097/MJT.0b013e3182979b59
Journal Title
American Journal of Therapeutics
First Page
107
Last Page
114
Document Type
Article
Publication Date
1-1-2015
Department
Medicine
Second Department
Pharmacology
Keywords
Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Coronary Restenosis, Humans, Renin-Angiotensin System, Vascular Diseases
Disciplines
Medicine and Health Sciences
Abstract
Postangioplasty restenosis remains a clinical problem, and various strategies have been used to minimize or eliminate this complication. Stimulation of the renin-angiotensin system has been shown to cause vascular smooth muscle migration, matrix deposition, and endothelial dysfunction, which are possible causes of postangioplasty restenosis, suggesting that the use of angiotensin-converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers might ameliorate or prevent restenosis. However, data obtained to date in both animal and human studies of various designs show conflicting results regarding the benefit or lack of benefit of angiotensin inhibition strategies. It has also been shown that the type of ACE genotype may influence the effects of drugs on restenosis, suggesting that in the future, a pharmacogenetic approach might be of use for augmenting the benefit in patients from inhibitors of the angiotensin system. As of now, there are no supportive data to suggest a benefit of using routine ACE inhibitors or angiotensin receptor blockers to prevent postangioplasty restenosis in the general population.
Recommended Citation
Liu, Y., Carrey, Z., Aronow, W. S., Alaie, D., Petrillo, R. L., & Frishman, W. H. (2015). The Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Postangioplasty Restenosis. American Journal of Therapeutics, 22 (4), 107-114. https://doi.org/10.1097/MJT.0b013e3182979b59
